神经炎症作为帕金森氏症和阿尔茨海默氏症疾病的联系:系统性审查和元分析
Anna Tylutka1, Piotr Żabiński2, Łukasz Walas3
1Department of Applied and Clinical Physiology, Collegium Medicum University of Zielona Gora, Zielona Gora, Poland.
Aging and disease
|January 3, 2025
概括
神经炎症在阿尔茨海默氏症和帕金森病患者中显著增加了IL-6,IL-1β和TNF-α等促炎细胞因子. 升高的IL-10可能表明在这些神经退行性疾病中起着保护作用.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 神经炎症是阿尔茨海默病 (AD) 和帕金森病 (PD) 的发展和进展的关键因素.
- 了解涉及的特定炎症标志物对于诊断和治疗这些神经退行性疾病至关重要.
研究的目的:
- 进行一项元分析,评估神经炎症在AD和PD的发病过程中的作用.
- 评估AD/PD患者和对照组之间的细胞因子水平差异.
主要方法:
- 在Web of Science和PubMed (2009-2023) 上进行了系统的文献搜索.
- 37个符合纳入标准的出版物被选择用于元分析.
- 统计分析包括计算细胞因子水平的标准化平均差异 (SMD) 和置信区间 (CI).
主要成果:
- 与对照组相比,患有AD和PD的患者表现出显著更高的IN-6 (IL-6) 水平.
- 阿尔茨海默病患者的IL-1β水平升高,而PD患者的IL-6和瘤缩因子-α (TNF-α) 水平升高.
- 抗炎细胞因子IL-10在两组中都显示出显著的差异,这表明它可能具有保护作用.
结论:
- 阿尔茨海默氏症和帕金森病与明显的炎症反应有关.
- 这些神经退行性疾病的特征是高水平的促炎细胞因子 (IL-6,IL-1β,TNF-α).
- IL-10可能起着保护作用,因此需要在神经退行性疾病背景下进行进一步的研究.
更多相关视频
14:45Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
6.3K
07:31Brain Ventricular Microinjections of Lipopolysaccharide into Larval Zebrafish to Assess Neuroinflammation and Neurotoxicity
Published on: August 23, 2022
3.3K
相关概念视频
Neural Regulation
38.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
38.9K
Disorders of the Nervous Tissue
926
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises...
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises...
926
Parkinson's Disease: Overview
303
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
303
Parkinson's Disease: Treatment
148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
Alzheimer's Disease: Overview
311
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
311
Alzheimer's Disease: Treatment
125
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
125
